Horne, ZD and Clump, DA and Vargo, JA and Shah, S and Beriwal, S and Burton, SA and Quinn, AE and Schuchert, MJ and Landreneau, RJ and Christie, NA and Luketich, JD and Heron, DE
(2014)
Pretreatment SUV<inf>max</inf> predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy.
Radiation Oncology, 9 (1).
Abstract
Background: This retrospective study aims to assess the usefulness of SUVmax from FDG-PET imaging as a prognosticator for primary biopsy-proven stage I NSCLC treated with SBRT.Methods: This study includes 95 patients of median age 77 years, with primary, biopsy-confirmed peripheral stage IA/IB NSCLC. All patients were treated with 60Gy in 3 fractions with a median treatment time of six days. Local, regional, and distant failures were evaluated independently according to the terms of RTOG1021. Local, regional, and distant control, overall- and progression-free survival were estimated by the Kaplan-Meier method. Cox proportional hazards regression was performed to determine whether SUVmax, age, KPS, gender, tumor size/T stage, or smoking history influenced outcomes. SUVmax was evaluated as both a continuous and as a dichotomous variable using a cutoff of <5 and ≥5.Results: Median follow-up for the cohort was 16 months. Median OS and PFS were 25.3 and 40.3 months, respectively. SUV with a cutoff value of 5 predicted for OS and PFS (p = .024 for each) but did not achieve significance for LC (p = .256). On Cox univariate regression analysis, SUV as a dichotomous variable predicted for both OS and PFS (p = .027 and p = .030, respectively). Defined as a continuous variable, SUVmax continued to predict for OS and PFS (p = .032 and p = .003), but also predicted LC (p = .045) and trended toward significance for DC (p = .059).SUVmax did not predict for OS as a dichotomous or continuous variable. It did, however, predict for PFS as a continuous variable (p = .008), neared significance for local control (p = .057) and trended towards, significance for distant control (p = .092).Conclusions: SUVmax appears to be a statistically and clinically significant independent prognostic marker for progression-free survival in patients with stage I NSCLC treated with SBRT. Prospective studies to more accurately define the role of tumor FDG uptake in the prognosis of NSCLC are warranted. © 2014 Horne et al.; licensee BioMed Central Ltd.
Share
| Citation/Export: |
|
| Social Networking: |
|
Details
| Item Type: |
Article
|
| Status: |
Published |
| Creators/Authors: |
| Creators | Email | Pitt Username | ORCID  |
|---|
| Horne, ZD | | | | | Clump, DA | dac158@pitt.edu | DAC158 | | | Vargo, JA | | | | | Shah, S | | | | | Beriwal, S | SUB45@pitt.edu | SUB45 | | | Burton, SA | | | | | Quinn, AE | | | | | Schuchert, MJ | mjs11@pitt.edu | MJS11 | | | Landreneau, RJ | | | | | Christie, NA | nac8@pitt.edu | NAC8 | | | Luketich, JD | luketich@pitt.edu | LUKETICH | | | Heron, DE | deh5@pitt.edu | DEH5 | |
|
| Centers: |
Other Centers, Institutes, Offices, or Units > Pittsburgh Cancer Institute |
| Date: |
30 January 2014 |
| Date Type: |
Publication |
| Journal or Publication Title: |
Radiation Oncology |
| Volume: |
9 |
| Number: |
1 |
| DOI or Unique Handle: |
10.1186/1748-717x-9-41 |
| Schools and Programs: |
School of Medicine > Cardiothoracic Surgery
School of Medicine > Radiation Oncology |
| Refereed: |
Yes |
| Date Deposited: |
02 Dec 2016 20:32 |
| Last Modified: |
22 Jun 2021 14:55 |
| URI: |
http://d-scholarship.pitt.edu/id/eprint/29605 |
Metrics
Monthly Views for the past 3 years
Plum Analytics
Altmetric.com
Actions (login required)
 |
View Item |
![[img]](http://d-scholarship.pitt.edu/style/images/fileicons/text_plain.png)
![[feed]](/images/feed-icon-32x32.png){kind=icon}